Outsourcing

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

A surge in capacity in contract microbial and mammalian cell-culture is underway to meet rising production needs for biopharmaceuticals.

CMOs Expand Biologics Manufacturing

The authors analyze the supply–demand trends for contract biologics manufacturing and the strategies of pharmaceutical and biotechnology companies and their suppliers in the value chain.

Evaluating Supply and Demand Patterns for Contract Biologics Manufacturing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Contract service providers should be concerned about the market perceptions of their performance.

Is "Satisfactory" Contractor Performance Good Enough?...

Henrik Johanning is CEO and specialist, Genau & Co, Denmark. He is also a member of Pharmaceutical Technology Europe’s Editorial Advisory Board.

One of the biggest barriers research and academic institutions face is the ability to get discoveries made in the lab into clinical testing. Because only small amounts of drugs are used in these early studies, they represent fewer potential risks for people in these trials.

A risk based approach to biopharmaceutical manufacturing

Is the lack of finance necessarily spelling doom for the European biotech industry?

Talking Point: Biopharm Investment

A CMO in Singapore manufacturing commercial biopharmaceuticals is the result of a partnership between two biopharmaceutical companies.

New biopharma CMO for Singapore

Too many players and threats to the main customer base challenge European dose manufacturers.

Contract Manufacturers Getting Squeezed

Patheon is betting the whole is worth more than the sum of the parts in its acquisition of Puerto Rico contract manufacturer Mova.

Patheon Places Big Bet with Mova Acquisition

The blockage in the new product pipeline may be breaking. CROs report increased demand for late-stage development services in their latest round of earnings reports.

Robust CRO Market Is Driving New Merger and Acquisition Activity

Early development services continue to be a sweet spot for contract R&D services. The big question is how soon the impact of early-development candidates will be felt in late development and commercialization.

Contract Manufacturing Services